Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02140814 · ClinicalTrials.gov registry record · Phase 2
Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease
A Phase 2 study of Polycystic Kidney Disease, sponsored by Alan Yu, MB, BChir.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT02140814 is a Phase 2 study of Polycystic Kidney Disease that has completed, run by Alan Yu, MB, BChir. The registered enrollment target is 10 participants, below the 331-participant average among 5 other Polycystic Kidney Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02140814, a Phase 2 study of Polycystic Kidney Disease, has completed, sponsored by Alan Yu, MB, BChir.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this pilot study is to evaluate the feasibility of administering niacinamide to patients with autosomal dominant polycystic kidney disease, to develop methods to assess the biological efficacy of niacinamide, and to perform a preliminary exploration of its clinical effect on kidney cyst growth and kidney function.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Niacinamide
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02140814
The ClinicalTrials.gov registry entry for NCT02140814 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 331-participant average among 5 other Polycystic Kidney Disease trials with a reported enrollment target (97% lower). The listed sponsor is Alan Yu, MB, BChir, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Polycystic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Niacinamide is the first listed.
NCT02140814 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT02140814 about?
NCT02140814 is a clinical study titled "Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease". The goal of this pilot study is to evaluate the feasibility of administering niacinamide to patients with autosomal dominant polycystic kidney disease, to develop methods to assess the biological efficacy of niacinamide, and to perform a preliminary exploration of its clinical effect on kidney cyst ...
What is the current status of trial NCT02140814?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2014-05.
What conditions does trial NCT02140814 study?
This clinical trial studies the following conditions: Polycystic Kidney Disease.
What interventions are being tested in trial NCT02140814?
The interventions under investigation include: Niacinamide (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02140814?
This trial is sponsored by Alan Yu, MB, BChir, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02140814 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycystic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.